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ABSTRACT 
The complex pathophysiology in beta-thalassemia can translate to multiple 
morbidities that affect every organ system. Improved survival due to advances in 
management meant that patients are exposed to the harmful effects of ineffective 
erythropoiesis, anemia and iron overload for a longer duration, and we started 
seeing new or more frequent complications in adult compared with younger patients. 
In this article, we highlight particular aspects of managing adult patients with beta-
thalassemia utilizing our own experience in treating such patients. We cover both 
transfusion-dependent and non-transfusion-dependent forms of the disease and 
tackle specific morbidities of highest interest. 
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INTRODUCTION 
The beta-thalassemias, a group of inherited hemoglobin disorders, continue to be a 
concern for health care systems owing to the high burden of disease and its 
management.1-3 The severity of ineffective erythropoiesis and subsequent anemia 
depend on several genetic and environmental factors and the disease phenotype 
was historically labelled as major, intermediate or minor accordingly.1 However, in 
more recent years, we started categorizing patients according to their transfusion 
requirement, to optimize practical management considerations, although beta-
thalassemia should always be considered a spectrum of severities with patients able 
to move from one to another as with management or natural progression of disease.4 
Transfusion-dependent beta-thalassemia (TDT) patients commonly present to our 
clinics in early childhood with severe anemia that requires life-long regular 
transfusion therapy for survival. On the other hand, non-transfusion-dependent beta-
thalassemia (NTDT) patients, usually present later in childhood or even in adulthood 
with mild/moderate anemia which only requires occasional or short-course regular 
transfusions in certain clinical settings. Recent management guidelines have also 
taken this direction of classification into TDT and NTDT in their recommendations.1,5-
7
  
 Over the last few decades, there has been a considerable advance in 
understanding the disease process of beta-thalassemia and key milestones in 
optimizing management with transfusion or iron chelation have been achieved. Such 
advances in supportive management led to a significant improvement in survival in 
this once fatal disease.8,9 For example, mortality rates in western cohorts have 
declined from 12.7 to 1.65 deaths/1000 patient-years between the periods 1980-
1999 and 1999-2013; with the leading cause of death moving from iron overload and 
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bone marrow transplant complications to infections and hepatitis C virus 
complications.10,11 However, such advances could not completely abolish the 
underlying pathophysiology which meant that several morbidities continue to 
manifest at higher incidence with advancing age and chronic exposure to risk 
factors. Moreover, increased awareness of the disease process prompted clinicians 
to apply closer and more regular monitoring which usually leads to higher detection 
of pre-clinical and clinical complications especially in adulthood. With this 
background, we herein share our experience in managing complications in adults 
with beta-thalassemia, especially in their mid-30s and beyond. We limited our 
coverage to select complications that we most commonly see in our clinics or those 
persistently reported at higher incidence with advancing age in the literature. It 
should be noted, however, that such morbidities can still manifest in younger patients 
especially with severe forms of the disease. Lastly, as clinical trials in this context are 
limited, we mostly relied on observational data from our own clinics or our expert 
opinion stemming from direct patient experience.  
 
GENERAL MANAGEMENT CONSIDERATIONS IN TDT 
In patients with TDT, the culprit of disease process is secondary iron overload from 
regular transfusion therapy, which can lead to organ damage and failure especially in 
the heart, liver, and endocrine glands.12 With advances in magnetic resonance 
imaging (MRI) that allowed non-invasive estimation of iron levels in key target 
organs13,14, we now realized that significant iron accumulation in these organs can 
start from early childhood15-18 and continues to accumulate over time if not optimally 
treated, leading to the emergence of clinical morbidities.19 It is hard to assign a 
specific age of incidence for the various potential complications, as it relies on the 
For personal use only.on October 24, 2018. by guest  www.bloodjournal.orgFrom 
Taher et al  How I Manage Adults with Thalassemia 
5 
specific transfusion and iron chelation practice and patient response. In sub-
optimally treated patients, we commonly experience an early onset of endocrine 
disorders in childhood, adolescence or early adulthood (growth failure, 
hypogonadism) with an increasing risk as patients age, in view of cumulative 
exposure as well as the underlying increased risk seen in the general aging 
population (e.g. hypothyroidism, hypoparathyroidism, diabetes, osteoporosis). Heart 
failure and arrythmias can be detected in early adulthood, again with an increasing 
risk as patients naturally age; while we tend to more commonly see arrythmias in 
older adults. Early signs of hepatic enzymes increase secondary to iron overload can 
be detected at any age, while overt hepatic disease such as fibrosis, cirrhosis or 
hepatocellular carcinoma are more time-dependent and we more commonly see 
them in older adults. Management of arrythmias and hepatic disease in adult 
patients are covered separately in the SPECIFIC MORBIDITIES section. In a 
nutshell, early optimization of transfusion and iron chelation therapy from childhood 
towards adulthood is essential to ensure adequate red blood cell supply while still 
prevent cumulative iron toxicity and subsequent morbidities, especially in later 
adulthood. More importantly, close and regular monitoring for clinical complications 
can ensure early detection, specialist consultation, and intervention.6 In Figure 1, we 
highlight key clinical and psychosocial concerns across age groups for patients with 
TDT. In Figure 2, we highlight standard monitoring recommendations to ensure early 
detection of abnormalities, although these could be adapted for specific patient 
populations with varying requirement. Monitoring recommendations for specific 
morbidities are further discussed in the SPECIFIC MORBIDITIES section. 
Although the three available iron chelators deferoxamine, deferiprone, and 
deferasirox have served patients well and have a large body of evidence for efficacy 
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in chelating iron from target organs6,20, we still see a considerable number of patients 
with high liver and cardiac iron concentration globally21, especially in older adults 
who were sub-optimally treated in childhood due to poor adherence to subcutaneous 
deferoxamine and imprecise iron measurement tools. Thus, as much as the onus is 
to prevent iron accumulation by optimal treatment from childhood, adult patients 
would require adequate chelation to decrease high iron levels to safety thresholds. 
All three iron chelators have established efficacy in significantly reducing iron levels 
from the liver and heart as evident from trials applying MRI technology.6,22-29 The 
question of which iron chelator is more effective or suitable as first line is futile, as 
management of patients should be individualized, and different iron chelators may be 
suitable for different iron overload profiles. Optimal dosing, side effect monitoring, 
and adherence are essential for any utilized iron chelator. In patients with 
established heart failure, we rely on continuous 24-hour deferoxamine infusion which 
was shown to improve cardiac function in earlier studies of TDT patients.30 Similar 
observations of cardiac function improvement and reversal of heart failure, were 
noted in trials of deferiprone monotherapy and the combination of deferiprone and 
deferoxamine.31-33 The details of management of cardiac complications can be found 
in the American Heart Association consensus statement on cardiac disease in 
thalassemia.34 Deferasirox is currently the only chelator to demonstrate stabilization 
or improvement in hepatic fibrosis.35 Non-clinical trial data have also demonstrated 
the ability of deferasirox or combination therapy in stabilization or reversal of 
endocrine and bone disease.36,37   
 
GENERAL MANAGEMENT CONSIDERATIONS IN NTDT 
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Anemia in NTDT can be progressive with age and is directly and independently 
associated with increased morbidity.38-40 Ineffective erythropoiesis also leads to a 
state of primary iron overload in the absence of transfusion therapy, driven by 
hepcidin dysregulation.41,42 Iron overload is cumulative over time and as patients 
advance in age38,43,44 with iron overload indices reaching clinically critical thresholds 
and associated with several morbidities in observational studies including hepatic 
fibrosis, thrombosis, pulmonary hypertension, endocrinopathies, osteoporosis, and 
cerebrovascular disease – with notable absence of cardiac iron loading.45,46 
Ineffective erythropoiesis can also lead to progressive bone marrow expansion and 
bone changes or mineral density reduction as well as hypercoagulability due to 
hemolyzed prothrombotic red cell production; the latter leading to vascular 
events.5,47-50 Thus, without intervention, NTDT patients experience increased 
morbidity as they advance in age with a notable incidence beyond the age of 35 
years38,40 – with some complications that are less commonly seen in patients with 
TDT (Figure 3). It should also be noted that quality of life is directly related to age 
and multiplicity of morbidity in NTDT; hence attention and appropriate psychological 
care should be administered.51 Management of select morbidities that we commonly 
encounter in adult patients at our clinics will be featured in the SPECIFIC 
MORBIDITIES section.  
In patients with NTDT, no formal clinical trials evaluated the role of regular 
transfusion therapy, as much as occasional transfusions are used in cases or 
pregnancy, surgery or during infections.7 We commonly restrict our use of regular 
transfusion therapy to specific clinical settings, such as in cases of growth failure or 
poor sexual development in childhood and adolescence. For adults, consideration of 
regular transfusion courses is also suggested for prevention or management of 
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certain morbidities (thrombotic events, pulmonary hypertension, leg ulcers, 
extramedullary hematopoietic pseudotumors) in high risk patients, backed-up by 
data on transfusion benefit from observational studies of our own patients.7,40 The 
need for transfusion therapy already indicates a more severe phenotype in NTDT 
that may warrant the need for continuous transfusions if the risk/benefit ratio is 
favorable.7 A careful attention should be made to the potential risks of iron overload 
and alloimmunization (especially in splenectomized, pregnant, or previously never 
transfused patients).7 We almost stopped relying at all on splenectomy owing to the 
large body of evidence on an increase of a variety of morbidities as well as infections 
in splenectomized patients.7,40 We mainly restrict it to patients with symptomatic 
splenomegaly or hypersplenism. Iron chelation now became standard of care for all 
patients over 10 years of age with iron overload.7 We commonly check all patients 
older than 10 years for iron overload with serum ferritin or MRI depending on cost 
and availability. Patients with iron overload (serum ferritin >800 µg/L or liver iron 
concentration >5 mg Fe/g dry weight)43,52 are started on iron chelation therapy with 
deferasirox.53-55 We follow dosing and iron assessment schedules from management 
guidelines.7  
 
SPECIFIC MORBIDITIES 
In this section we will feature clinical cases to illustrate the course and management 
of specific morbidities in patients with TDT or NTDT. These have been selected 
based on our experience of encountering them most commonly in adults with beta-
thalassemia, although they may still manifest earlier especially in severe or poorly 
managed patients. Other clinical complications which may manifest earlier in the 
natural course of beta-thalassemia and may also increase in incidence with 
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advancing age (e.g. heart failure, endocrine and bone disease, leg ulcers, 
extramedullary pseudotumors, gall stones, infections) have been featured 
elsewhere, and management guidelines for those are widely available.6,7,56 Lastly, 
we should also highlight that with advanced age comes an added risk of 
complications such as cancer, similar to the general population. One epidemiologic 
study found that the incidence of cancer (3.96/1000 person-years) in thalassemia 
patients was 52% higher than the general population, especially for hematological 
and abdominal malignancies.57 Iron overload and hepatitis C virus infection increase 
the risk of hepatocellular carcinoma in thalassemia, while oxidative stress in the 
bone marrow is suggested to increase the risk of hematologic malignancies.58,59 
 
Case 1: Arrythmia 
A 42-year-old man with TDT was admitted for evaluation of cardiac arrythmia. He 
was receiving 2-3 units of packed red blood cells every 21 days with a mean pre-
transfusional hemoglobin of 10.5 g/dL. His comorbidities included glucose 
intolerance, hypogonadotropic hypogonadism, and subclinical hypothyroidism. He 
started iron chelation therapy at 4 years of age with subcutaneous deferoxamine. 
Five years prior to the current presentation, his cardiac T2* MRI showed a moderate 
myocardial iron overload (14.4 ms), and deferiprone (75 mg/kg/day) was added to 
his iron chelation regimen in combination with deferoxamine (30 mg/kg/day). His 
cardiac T2* showed improvement to 24.5 ms three years after, and continues to be 
over 25 ms according to the latest imaging. He stared experiencing several episodes 
of arrythmia over the last two year (atrial tachycardia with 2:1 AV block/atrial flutter) 
which required frequent hospitalizations including the present one. Routine 
echocardiography has never shown any abnormalities or impairment of left 
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ventricular function except for a mild/moderate atrial dilatation. Subsequently, the 
patient was sent for catheter ablation. His last 24-hour electrocardiogram (ECG) 
showed normal sinus rhythm with AV block (Grade 1). He was discharged on 
bisoprolol 1.25 mg twice daily and amiodarone 200 mg once daily. 
 
Arrythmia 
With advances in cardiac MRI imaging and the availability of oral iron chelators with 
improved adherence and efficacy in cardiac iron removal, the incidence of heart 
failure and its associated fatality in TDT patients continue to decline.6,10 However, 
this delay or prevention in heart failure allowed other cardiac manifestations to 
become more apparent in older adults with thalassemia, such as arrythmias 
(especially atrial fibrillation with a prevalence of around 40% in patients over 40 
years), cardiac function changes due to restriction, fibrosis and arterial changes due 
to loss of vascular compliance.6 Symptomatic arrhythmias in thalassemia patients 
pose a significant clinical risk and are associated with significant myocardial iron 
overload. They can also occur in patients with otherwise normal iron levels, this 
being attributed to fibrosis from past iron deposition that was cleared.6 Patients 
should be assessed by history taking for symptoms on every visit, and ECGs should 
be done annually for all patients, biannually in asymptomatic patients with 
abnormality, and monthly or more frequently in symptomatic patients. Assessment 
can follow the course of echocardiographic or cardiac T2* measurement and should 
not be ignored. The emerging role of MRI measurement of cardiac fibrosis can also 
be considered.  
In the presence of known or suspected severe cardiac iron overload, we 
intensify iron chelation therapy when these symptomatic arrythmias manifest, even if 
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cardiac MRI assessment of myocardial iron status is not feasible, especially as a 
matter of urgency if the symptoms include syncope or pre- syncope. Arrhythmias in 
TDT patients can often be controlled or eliminated by aggressive iron chelation, with 
intravenous deferoxamine or high dose deferiprone monotherapy or combination.60 
However, this may require some time and short-term antiarrhythmic therapy is 
needed in consultation with a cardiologist in view of the constantly changing practice 
in rhythm control, and the different approaches needed for different arrythmias. 
Although with low evidence, amiodarone has been used in the limited setting of 
inpatient and acute care because of its broad spectrum of action and modest 
compromise of cardiac function.34 It should be noted, however, that amiodarone 
therapy is associated with side effects especially relevant for patients with 
thalassemia, particularly for liver and thyroid function which would require close 
monitoring. Beta-blockers are generally well tolerated, if titrated slowly, and can be 
useful in controlling ectopic rhythms.34 Catheter ablation may be considered in 
patients with chronic symptomatic arrhythmias, but patients should be referred to a 
cardiac electrophysiology specialist before ablation given fibrosis can be challenging 
to ablate. 
It should be noted that arrythmias may not always be due to iron overload in 
beta-thalassemia, particularly in younger adults who present with supraventricular 
arrhythmia. In such cases, other causes such as alcohol or substance abuse or 
excess of thyroid hormones should be ruled out. 
 
Case 2: Liver disease 
A 42-year-old man with TDT presented with right upper quadrant pain that has been 
persistent for four months. Initial imaging with contrast-enhanced computed 
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tomography showed foci in his liver which were initially interpreted as extramedullary 
hematopoiesis. Liver function tests were within normal range, as well albumin level 
and prothrombin time. His ferritin level was 3100 µg/L and his liver iron concentration 
was also measured by MRI and was 17.3 mg Fe/g dry weight. A computed 
tomography-guided biopsy was recommended and showed the lesions to be 
compatible with multifocal hepatocellular carcinoma. Hepatitis B and C testing by 
polymerase chain reaction were negative. The patient received palliative treatment. 
He developed hepatorenal syndrome and rapidly succumbed to his illness. 
 
Liver disease 
Liver disease is becoming a leading cause of mortality in TDT, especially owing to 
the decline in mortality from heart failure associated with advances in cardiac iron 
monitoring and effective chelation therapy.61 Liver disease is also responsible for 
around 10% of causes of death in NTDT patients.62 The liver is the primary site of 
storage for excess iron; hence, in the absence of effective iron chelation therapy, 
liver iron concentration can reach clinically critical levels in both TDT and NTDT 
patients, although at slower rates in NTDT. Primary iron overload from increased 
intestinal iron absorption in NTDT leads to preferential portal and hepatocyte iron 
loading while hepatic loading in TDT patients also involved the reticuloendothelial 
system.6,7 Irrespectively, chronic hepatic iron deposition promotes liver fibrogenesis 
and cirrhosis in both patient populations.63,64 43,52,65,66  A longer duration of hepatic 
iron exposure is associated with a higher risk of significant fibrosis and cirrhosis, 
hence why overt morbidity primarily manifests in older adults.67,68 In regularly 
transfused patients, hepatic disease may also be caused or exacerbated by hepatitis 
C (and less commonly B) virus infection. Although the incidence of viral hepatitis 
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substantially declined after the introduction of regular donor screening programs in 
the 1990s and further with the introduction of RNA-PCR testing, adults who may 
have acquired it earlier continue to have a high prevalence.  Hepatitis C virus 
infection and iron overload are independent risk factors for hepatic fibrosis and 
cirrhosis, although their co-existence is synergistic in injury.66 
Both hepatic iron overload and chronic hepatitis C virus (and less so hepatitis 
B virus) infection can lead to hepatocellular carcinoma. The carcinogenicity of iron is 
related to its induction of oxidative damage, which results in genotoxicity, and to 
immunologic dysregulation, which attenuates cancer immune surveillance. Chronic 
hepatitis C infection leads to necroinflammation, which can prompt progression to 
cancer.69 Several cases of hepatocellular carcinoma in patients with TDT and NTDT 
from our clinics or those of colleagues have been described in the literature. Most 
cases occurred in older adults (>45 years) who had cirrhosis and viral hepatitis 
infection, although malignancy occurred in some patients the absence of viral 
hepatitis or cirrhosis while having considerably high iron overload levels.69-74 
Additional factors such as obesity or alcohol consumption may also increase 
steatosis and oxidative stress, which accelerate liver iron uptake and increase risk of 
liver fibrosis, cirrhosis, and cancer in beta-thalassemia patients.75 
Our approach for the diagnosis and management of liver disease in beta-
thalassemia is summarized in Figure 4. The hallmark is close monitoring not only for 
iron overload levels or hepatitis infection status but also for hepatic injury. Optimal 
management of iron overload is key to prevent liver toxicity. All three available iron 
chelators have data on efficacy in hepatic iron reduction on MRI, although 
deferasirox has the largest body of evidence in severely iron loaded patients (liver 
iron concentration >15 mg Fe/g dry weight)25-27 and has demonstrated ability to 
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reduce necroinflammation and fibrosis in a significant proportion of patients on three 
years therapy.35 Management of viral hepatitis should be done in consultation with 
an experienced hepatologist, especially in pregnant women, immunosuppressed 
patients, and those with cirrhosis.6,7 Earlier studies of antiviral therapy in beta-
thalassemia with peg-interferon and ribavirin showed sustained virological responses 
in 25-64% of patients.76 However, ribavirin is known to be associated with worsening 
anemia and increased transfusion demands, which is a major concern in beta-
thalassemia patients. Moreover, most clinicians today opt to go for interferon-free 
regimens. The remarkable revolution in hepatitis C management with direct-acting 
antiviral drugs offers a new opportunity for beta-thalassemia to receive once-daily 
treatments with no need to check for genetic polymorphisms, and with treatment 
schedules typically lasting 8-12 weeks (e.g. glecaprevir-pibrentasvir, ledipasvir-
sofosbuvir, or sofosbuvir-velpatasvir for genotype 1). In observational studies and 
small trials, sustained virological responses at 12 weeks were reported in up to 90-
100% irrespective of cirrhosis status.77-80  In a recent review, data compiled from 420 
thalassemia patients across different studies, with genotypes 1a, 1b, 2, 3 and 4, 
showed a success rate of at least 93% with direct-acting antiviral drugs.81 Thus, 
hepatitis C virus infection in beta-thalassemia today is definitely treatable, and much 
more conveniently than before.  
Once manifested, HCC would be managed according to standard of care and 
stage of the disease using chemotherapy, targeted or immune therapy, 
radiofrequency ablation, transplant, or palliative care. Effective HCV clearance in 
patients with HCC improves survival and recurrence rates, but the role of iron 
chelation in this setting has not been fully evaluated.82 
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Case 3: Thrombotic disease 
A 38-year-old splenectomized man with NTDT presented with severe right calf pain. 
The pain started four days prior to presentation, intensified gradually, and was 
associated with a sensation of hotness around the area. No history of trauma or 
fever was reported and no personal or family history of thrombosis was documented. 
A thrombophilia workup was also negative. The pain was unresponsive to 
analgesics. On physical examination, the patient had diffuse erythema in the right 
calf which was hot and tender to palpation. No edema was noted. Laboratory work-
up revealed a total hemoglobin level of 8.4 g/dL, a nucleated red blood cell count of 
460 x 106/L and a platelet count of 986 x 109/L. Duplex ultrasonography revealed 
deep thrombosis of the posterior tibial vein. The patient was started on a treatment 
dose of low-molecular weight heparin and was started on a course of regular 
transfusion therapy. Aspirin was also initiated.  
 
Thrombotic disease 
A hypercoagulable state has been identified in beta-thalassemia patients.83,84 It is 
primarily attributed to abnormalities in platelets and pathological red blood cells, 
although several additional factors are believed to be involved, including endothelial 
dysfunction, coagulation system abnormalities and presence of microparticles, 
ultimately leading to clinical thrombosis.50 The incidence of clinical thrombosis is 4-
fold higher in NTDT compared with TDT patients, is mostly venous, and is a leading 
cause of mortality.85,86  The frequency of thrombosis in NTDT is significantly higher in 
patients >35 years (28.2%) compared to patients 18-35 years (14.9%) or younger 
than 18 years (4.1%).40 Splenectomy, anemia (hemoglobin level <9 g/dL), and iron 
overload (serum ferritin >800 µg/L or liver iron concentration >5 mg Fe/g dry weight) 
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have all been identified as a risk factors.40,43,52,85,87 Additionally, high nucleated red 
blood cell (≥300 x 106/L) and platelet counts (≥500 x 109/L) were shown to further 
substantiate the risk in splenectomized NTDT patients.86 Although the incidence of 
overt strokes is relatively low (~5%)85,86, silent strokes have been described in up to 
60% of splenectomized adults (mean age 32 years) with NTDT, with a clear 
correlation with advancing age.88,89 The clinical significance of these white matter 
lesions or whether they require any intervention, however, is not yet clear.  
 We treat patients who develop thrombotic disease as per standard local or 
international guidelines for non-thalassemic patients. Patients who present with 
unprovoked, spontaneous thrombosis at unusual sites are also worked up for 
thrombophilia despite the established risk in thalassemia. For primary or secondary 
prevention, data on risk stratification or prophylaxis in thalassemia are lacking and 
the approach is mostly individualized. We commonly consider beta-thalassemia 
patients as high-risk in medical and surgical settings, especially patients with the 
aforementioned thalassemia-related (e.g. NTDT, splenectomy, low hemoglobin, high 
platelet or nucleated red blood cell counts) and non-related (e.g. older age, 
pregnancy, malignancy, immobility, previous history of thrombosis) risk factors.  If 
prophylaxis is deemed necessary, we commonly use enoxaparin. Newer oral 
anticoagulants may also be considered, while also acknowledging lack of data in 
thalassemia, especially if long-term prophylaxis is needed. Blood transfusions may 
control the hypercoagulability in NTDT patients by improving ineffective 
erythropoiesis and decreasing the levels of pathological red blood cells with 
thrombogenic potential.90 In observational studies from our clinics, transfusion 
therapy has been associated with lower rates of thromboembolic events.40 It should 
be noted that a specific transfusion schedule or duration for such patients is not 
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defined. In our practice, we often rely on less frequent regular transfusions to lower 
the risk of iron overload. These practices should be individualized and based on 
clinical patient response. The association between high platelet counts or platelet 
activation and thrombosis as well as a lower recurrence rate of thrombotic events in 
splenectomized NTDT patients who took aspirin after their first event, when 
compared to those who did not, suggests a potential role for aspirin in 
prevention.85,86 We commonly administer aspirin therapy in all splenectomized 
patients irrespective of platelet count. 
 
Case 4: Pulmonary hypertension 
A 46-year old splenectomized woman with NTDT presented with progressive 
dyspnea of two weeks duration. She had no prior history of cardiac disease. Her 
laboratory studies revealed a total hemoglobin level of 10.2 g/dL, a platelet count of 
850 x 109/L, and a serum ferritin level of 1520 µg/L. On continuous-wave Doppler 
transthoracic echocardiography she had a peak tricuspid-valve regurgitant jet 
velocity (TRV) of 3.5 m/s. She was referred to an interventional cardiologist and 
underwent a right heart cardiac catheterization which revealed a mean pulmonary 
arterial pressure of 45 mm Hg. She was started on anticoagulant and regular 
transfusion therapy. She was asked to present back for re-evaluation with 
echocardiography in 6 months.    
 
Pulmonary hypertension 
Although the exact mechanisms implicated in the pathogenesis of pulmonary 
hypertension in beta-thalassemia remain unclear, its association with anemia, 
hemolysis and hypercoagulability as well as complex interaction of platelets, the 
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coagulation system, erythrocytes, and endothelial cells along with inflammatory and 
vascular mediators are suggested.91-93 Pulmonary hypertension in beta-thalassemia 
is pulmonary arterial hypertension, characterized by the presence of pre-capillary 
pulmonary hypertension in the absence of left-sided heart disease, lung disease, or 
chronic thromboembolism.94-96 However, the possibility of pulmonary hypertension 
occurring secondary to chronic thromboembolic disease cannot be fully excluded 
with the hypercoagulable state noted in beta-thalassemia.97,98 In newer classification, 
it would belong  to Group 5 pulmonary hypertension associated with chronic 
hemolytic anemia with unclear/multifactorial mechanism.99 
Historic studies relying primarily on echocardiographic criteria (TRV 
exceeding 2.5-2.8 m/s) to document pulmonary hypertension in beta-thalassemia 
provide an overestimate of its prevalence.7,40 In a more recent large study of around 
1300 patients from Italy, the prevalence of pulmonary hypertension was considerably 
lower when more strict echocardiographic criteria and confirmatory right heart 
catheterization were used (5.7% for a TRV >3.0 m/s, 3.6% for a TRV >3.2 m/s, and 
2.1% on right heart catheterization). Patients with NTDT had a 5-fold increased 
prevalence compared with TDT (4.8% vs. 1.1%).100 Right heart catheterization is 
needed to confirm the diagnosis. Even in studies relying on catheterization, a 
significant correlation was noted between prevalence and age, with an exponential 
rise noted after the age of 45 years.100 Splenectomy, a history of thrombosis, a 
platelet count ≥500 x 106/L, a nucleated red blood cell counts ≥300 x 106/L, and iron 
overload (serum ferritin >800 µg/L or liver iron concentration >5 mg Fe/g dry weight)  
have all been reported as risk factors for pulmonary hypertension in NTDT 
patients.40,43,52,98,100   
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When manifest, pulmonary hypertension is associated with functional 
limitation and can lead to right-sided heart failure.97,100-106 Our approach for the 
diagnosis, prevention and management of pulmonary hypertension in beta-
thalassemia is summarized in Figure 5. Although no clinical trials exist, a role for 
transfusion therapy in preventing the occurrence of pulmonary hypertension is 
suggested in observational studies, but the specific schedule and duration of use are 
not defined and should be individualized.40,98,107 Similar effects were also noted with 
hydroxyurea therapy 40,98,108-111 and iron chelation therapy in observational 
studies.40,98 For management, sildenafil citrate showed promising results in small 
studies112-114 and trials by improving cardiopulmonary hemodynamics in patients with 
a TRV >2.5 m/s.115 Its use however should be limited to patients with confirmed 
pulmonary hypertension by cardiac catheterization. 
 
FUTURE PROSPECTS 
Several novel therapies are being developed for patients with beta-thalassemia. 
Gene therapy to replace the defective beta-globin gene has already shown 
promising results in reducing or eliminating transfusion requirement in TDT 
patients116, while genome editing to reinstate  the capacity of fetal hemoglobin 
production is underway.117 JAK2 inhibitors have also shown some positive results in 
ameliorating splenomegaly in TDT, although with a modest effect on transfusion 
requirement.118 The ligand traps sotatercept and luspatercept have shown promising 
results in phase 2 studies with significant reduction in transfusion requirement for 
TDT patients and increase in hemoglobin level in NTDT patients, and data from 
randomized clinical trials are awaited.119,120 Hepcidin agonists are also being 
evaluated for their ability to prevent iron overload and improve anemia in beta-
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thalassemia patients.121 Reductions in transfusion requirement and subsequent 
prevention of iron overload in TDT and improvement in anemia with prevention of 
iron overload in NTDT will surely translate to reduced morbidity risk. Although we 
expect that such agents, if successful in clinical trials, can transform the disease 
picture for younger patients and become the mainstay of therapy; older patients who 
have been exposed to the damaging effects of anemia and iron overload for decades 
will continue to require conventional therapy for optimal management of their 
complications risk.  
 Beta-thalassemia is a disease of multiple risk factors and multiple morbidities, 
which logically implies the need for a multidisciplinary management team. This 
becomes particularly essential for older patients with co-morbidities, that require the 
attention of internists and specialists alongside their primary care. Transition from 
child into adult care facilities becomes more essential for older patients. That said, 
the ideal treatment strategy will always be an individualized one.  
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FIGURE LEGENDS 
Figure 1. Management priorities across age groups in transfusion-dependent-
thalassemia. The listing reflects potential incidence of morbidities in respective age 
groups, but is not exclusive, and individual patients may have different needs. 
aIncludes diabetes mellitus, hypothyroidism, hypoparathyroidism, osteoporosis, 
hypogonadism. 
 
Figure 2. General monitoring recommendations across age groups in transfusion-
dependent-thalassemia. aBy MRI R2 for liver or MRI T2* for liver and heart with 
appropriate calibration. LIC and cardiac T2* may be assessed at earlier age (from 6 
years) if feasible especially in patients who are on high iron intake. bAs assessed by 
experienced echocardiographer or cardiac MRI. cAlanine aminotransferase, 
aspartate aminotransferase, total and direct bilirubin. dThyroid stimulating hormone; 
calcium, phosphate, vitamin D and parathyroid hormone (as indicated); luteinizing 
hormone, follicle-stimulating hormone, testosterone, estradiol, gonadotropin-
releasing hormone (as indicated in cases of abnormal sexual development); fasting 
blood sugar, oral glucose tolerance test (as indicated). Q, every; LIC, liver iron 
concentration; LVEF, left-ventricular ejection fraction; TRV, tricuspid-regurgitant jet 
velocity; ECG, electrocardiogram; US, ultrasound; TE, transient elastography; BMD, 
bone mineral density.  
 
Figure 3. Morbidities and risk factors in patients with non-transfusion-dependent 
thalassemia. The figure illustrates risk factors and pathophysiologic mechanisms as 
Venn diagrams with notable morbidities associated with them included within. Some 
morbidities are attributed to more than one risk factor. These associations are mostly 
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based on data from observational studies. EMH, extramedullary hematopoietic 
pseudotumors; IE, ineffective erythropoiesis, PHT, pulmonary hypertension; GFR, 
glomerular filtration rate. aAs evident on fluorodeoxyglucose PET-CT.  
 
Figure 4. Approach to monitoring and management of liver disease in adult beta-
thalassemia patients. aBy MRI R2 or T2*, the latter requiring appropriate calibration 
and preferred if cardiac iron assessment is required at the same time. MRI 
monitoring can start at the age of 10 years in TDT (or earlier if feasible and deemed 
necessary) and NTDT. bif not anti-HBsAg positive. NTDT, non-transfusion-
dependent beta-thalassemia; TDT, transfusion-dependent beta-thalassemia; SF, 
serum ferritin; LIC, liver iron concentration; Q, every; HCV, hepatitis C virus; HBV, 
hepatitis B virus; HAV, hepatitis A virus; LFT, liver function tests; RNA-PCR, 
ribonucleic acid polymerase chain reaction; MRI, magnetic resonance imaging; US, 
ultrasound; ULN, upper limit of normal; DAA, direct-acting antiviral drugs. 
 
Figure 5. Approach to diagnosis, prevention and management of pulmonary 
hypertension in adult patients with beta-thalassemia. aPatients with TRV <2.5 m/s 
may also be re-assessed but at longer intervals (3-5 years). NTDT, non-transfusion-
dependent beta-thalassemia; TDT, transfusion-dependent beta-thalassemia; nRBC, 
nucleated red blood cell count; PHT, pulmonary hypertension; TRV, tricuspid-valve 
regurgitant jet velocity. 
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Anemia and iron overload
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Iron intake
Serum ferritin
LICa
Cardiac T2*a
Growth
Liver status
Liver US
Endocrine labsd
BMD
Record at every transfusion | Yearly assessment of iron intake based on transfusion burden
Q 1-3 months
Q 2 years if <3 mg/g | Q 1 year if 3-15 mg/g | Q 6 months if >15 mg/g or rapidly increasing trend in serum 
ferritin/LIC 
Q 2 years if ≥30 ms | Q 1 year if ≥10 to <30 ms | Q 6 months if <10 ms
Weight every visit | Standing/Sitting Height Q 6 months | Bone Age Q 1 year if delayed puberty/growth
Enzymesc: Q 3 moths | Q 1 month if >5 ULN | Virology: Q 1 year
Q 1 year | Q 6 months if abnormal. TE assessment 
may also be done if available.
Q 6 months to 1 year | Q 3 to 6 months as needed in patients with abnormality
Q 2 years | Q 1 year as needed in patients with abnormality
Age <10 years
LVEFb
Q 1 year if ≥56% | Q 3- 6 months if <56% | Q 1-3 months if <56% and symptomatic | TRV assessment can also be 
done as needed and simultaneous ECG measurement should be conducted
10-18 years >18 years
Sexual 
development Tanner staging Q 1 year
Weight every visit
Routine assessment for infertility,
secondary hypogonadism, impotence
Figure 2.
Other Psychosocial assessment for patient and family
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Iron Overload Viral hepatitis
Hepatic disease
• LFTs: Q 3 months or Q 1 month if >5 ULN
• Liver US: Q1 year or Q6 months if abnormal
• Transient elastography (measure of hepatic 
stiffness indicative of fibrosis): Q 1-2 years if 
available
• Optimize iron chelation in iron overload
• Optimize antivirals in viral hepatitis
• Lifestyle modifications
Monitor Prevent
• Consult hepatologist
• Optimize iron chelation
Treat
• Serology for HCV and HBVb Q 1 year in transfused 
patients, positive results confirmed with RNA-
PCR, on-treatment monitoring as recommended
Monitor
• Vaccinate for HBV if to start transfusion
• Vaccinate for HAV
Prevent
• DAA (preferred) or peg-interferon plus ribavirin 
• Consult hepatologist
Treat
• LICa Q 2 years if <5 NTDT or <3 TDT, Q 1 year if 5-15 
NTDT or 3-15 TDT, Q 6 months if >15 mg/g
• Serial SF Q 1-3 months TDT and 3-6 months NTDT
Monitor
• Optimize chelation to iron intake
• Ensure adherence to chelation
Prevent
• Optimize chelation to baseline iron levels
• Ensure adherence to chelation
Treat
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RISK FACTORS FOR PHT
• NTDT
• Sub-optimally transfused TDT
• Splenectomy
• Platelet count ≥500 x 109/L
• nRBC ≥300 x 106/L
• Hemoglobin level <9 g/dL
• Significant iron overload 
• History of thrombosis
• Other conventional risk factors for PHT
Annual TRV 
by echocardiography
TRV 2.5-3.2 m/s and asymptomatica TRV 2.5-3.2 m/s and symptomatic TRV >3.2 m/s
Send to right heart catheterization• Consider regular transfusion if NTDT
• Optimize regular transfusion if suboptimal in TDT
• Consider hydroxycarbamide
• Optimize iron chelation
• Consider anticoagulant therapy
• Consult cardiologist
• Manage per PHT guidelines
_
+
Close monitoring and 
cardiology consult
Rule out other causes for
Symptoms
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